Exchange: NASDAQ·Updated 07:30 PM EDT

TLX News

News
all
press releases
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
More News
Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse
Telix Pharmaceuticals acquires ITM Isotope for $1.65B to create a radiopharmaceutical leader. Here is what investors need to know.read more...
Benzinga
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.read more...
Benzinga
Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX,TLX.AX) announced that it signed an agreement to acquire privately held ITM Isotope Technologies Munich SE in a transaction valued at up to US$2.35 billion, strengthening its position in the global radiopharmaceutical and radioisotope m...
Nasdaq News: Markets
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
FDA approves Telix Pharmaceuticals' Pixclara, the first radiopharmaceutical brain cancer imaging drug for glioma PET scans.read more...
Benzinga
TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent
The FDA’s target date for deciding on Pixclara is September 11.
Stocktwits
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a radiopharmaceutical company, reported a rise in revenue for the second quarter, helped by the increased revenue from the precision medicine business...
Nasdaq News: Markets
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine research firms that are presently covering the stock...
MarketBeat
Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End
Telix Pharmaceuticals (NASDAQ:TLX) hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical...
MarketBeat

Advertisement|Remove ads.